BIOCON PHARMA LIMITED

Zydus Lifesciences received USFDA approval for generic Enzalutamide capsules (40 mg), indicated for metastatic castration-resistant prostate cancer, with annual US sales of USD 869.4 million. Biocon's Bengaluru API facility received four observations from USFDA, with no foreseen business impact.

Biocon partners with Tabuk Pharmaceuticals to commercialize GLP-1 products for diabetes and weight management in the Middle East. Biocon will develop and manufacture the products, while Tabuk will handle marketing, registration, and importation, with potential for local manufacturing.

The Union government's Vigyan Dhara initiative, with a Rs. 10,000 crore outlay, aims to enhance biotech research and manufacturing efficiency. It focuses on human capacity building, R&D, and technology deployment, aligning with national missions like Aatmanirbhar Bharat and Make in India. The initiative seeks to prevent duplication and concentrate on critical areas for sustainable growth, including bio-therapeutics, bio-fuels, and marine applications.

Regulatory snapshots: global drug submissions, approvals, clinical trial approvals, and other decisions involving Amplia, Apellis, Biocon, Biotech, Ipsen, Janssen, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, Samsung Bioepis, Sanofi.

HFCL partners with GA-ASI for UAS sub-systems, Dreamfolks Services addresses disruption, Sterling and Wilson Renewable Energy CFO resigns, Ugro Capital postpones board meeting, Aster DM Healthcare leases land for new hospital, Vodafone Idea signs $3.6 billion network deal, ONGC Videsh secures gas deal in Azerbaijan, USFDA inspects Glenmark Pharmaceuticals with no observations, Ramco Cements expands capacity, BHEL awarded NTPC contract, Reliance Industries extends call money payment deadline, USFDA inspects Aarti Drugs with Form 483 observations, Tata Steel commissions India’s largest blast furnace, Avalon Technologies CFO resigns, USFDA inspects Dr Reddy’s Laboratories with zero observations, HDFC Bank approves HDB Financial Services IPO, Bharat Forge enters renewable energy agreement, Signature Global CFO resigns, JM Financial reappoints and appoints MDs, Adani Total Gas secures international financing, Godfrey Phillips India considers bonus shares, Mankind Pharma approves fund raising, Vanguard Group Inc buys stakes in various companies.

Biocon received 3 observations from USFDA after inspection of Bengaluru API facility. Aarti Drugs received 7 observations from USFDA after inspection of Tarapur API facility. Glenmark Pharmaceuticals received zero observations from USFDA after inspection of Aurangabad formulation facility.

Graft versus Host Disease Market to grow at 9.9% CAGR (2020-2034), driven by branded therapies, strong pipeline, and increased awareness. Market size in the US was $1 billion in 2023, expected to grow at 7.4% CAGR (2024-2034). Emerging therapies like Axatilimab and CSL964 to transform market. Key companies include Equillium, Biocon, Takeda, and CSL Behring.

The graft versus host disease market is growing due to the adoption of branded therapies like JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK, a strong pipeline with over 10 new drugs expected to launch, and increased awareness of GvHD management. Innovative treatments and ongoing research aim to address unmet needs in this complex condition.

The global erythropoietin drugs market is projected to grow at a CAGR of 3.8% from 2024 to 2034, reaching $14.3 billion by 2034. Advances in precision medicine, regulatory reforms for biosimilars, and telemedicine integration are driving market growth. Key players include Amgen, Roche, and Johnson & Johnson. Epoetin Alfa and biosimilars lead the market segments.

Biology is revolutionizing healthcare through genetics, Omics, RNA, and CRISPR, potentially curing genetic diseases. India aims to lead this transformation with its scientific talent and technological capabilities. Biotechnology is increasingly interconnected with other fields, driving innovation in medicine and beyond.